Metacrine Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
MTCR
- Share Price
-
$0.48
- (As of Friday Closing)
Metacrine General Information
Description
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
- 4225 Executive Square
- Suite 600
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Metacrine Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.48 | $0.48 | $0.30 - $0.68 | $20.6M | 42.6M | 324K | -$1.02 |
Metacrine Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (21,268) | (22,654) | 106,008 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (36,100) | (60,135) | (35,855) | (29,174) |
| Net Income | (38,189) | (62,207) | (37,304) | (28,933) |
| Total Assets | 55,037 | 79,989 | 104,236 | 60,281 |
| Total Debt | 13,788 | 14,309 | 11,120 | 11,447 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Metacrine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Metacrine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Metacrine Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapi
Pharmaceuticals
San Diego, CA
10
As of 2022
00000
000
0000-00-00
000000&0
000000
iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Morristown, NJ
000
As of 0000
00000
000000 - 000
00000
0000 0
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
000000000000000
Newton, MA
00
As of 0000
000.00
000000000
000.00
Add Comparison
Metacrine Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intercept(Biotechnology) | Formerly VC-backed | Morristown, NJ | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Newton, MA | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Newark, CA | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Corporation | Austin, TX | 00 | 0000 | 00000000 | 0000 |
| 00000000 | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
Metacrine Patents
Metacrine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021236648-A1 | Crystalline forms of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | 0000000000 | |
| CA-3171987-A1 | Crystalline forms of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | 0000000000 | |
| EP-4121010-A1 | Crystalline forms of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | 0000000000 | |
| EP-4121012-A1 | Formulations of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | 0000000000 | |
| AU-2021239956-A1 | Formulations of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | A61K9/1635 |
Metacrine Executive Team (15)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michael York | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| Nicholas Smith Ph.D | Senior Vice President, Chemistry | ||
| Theresa Lowry | Executive Vice President Human Resources | ||
| Preston Klassen MD | President and Chief Executive Officer | ||
| Richard Heyman Ph.D | Co-Founder & Executive Chairman |
Metacrine Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amir Nashat Ph.D | Polaris Partners | Board Member | 000 0000 |
| Andrew Guggenhime | Self | Board Member | 000 0000 |
| Jeffrey Jonker JD | Self | Board Member | 000 0000 |
| John McHutchison MD | Self | Board Member | 000 0000 |
| Julia Owens Ph.D | Metacrine | Board Member | 000 0000 |
Metacrine Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Metacrine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Metacrine ESG
Risk Overview
Risk Rating
Updated June, 10, 2021
32.71 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 427
Rank
00.00
Percentile
